Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1319630 | 1.00 | GAA (0.32) | GAA | |
| SCHEMBL12120940 | 0.80 | ATM (0.49) | GAA | |
| SCHEMBL1321754 | 0.78 | KMT2A (0.46) | GAA | |
| SCHEMBL1319894 | 0.72 | GAA (0.42) | GAA | |
| SCHEMBL1319896 | 0.72 | GAA (0.42) | GAA | |
| SCHEMBL1321565 | 0.71 | GAA (0.58) | GAA | |
| SCHEMBL12473973 | 0.65 | GRIN2D (0.49) | GAA | |
| SCHEMBL3257590 | 0.63 | KDM1A (0.48) | — | |
| SCHEMBL3503959 | 0.63 | KDM1A (0.48) | — | |
| SCHEMBL6983785 | 0.58 | NPC1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348016-B1 | Phenyl pyrrole aminoguanidine derivatives | SYNACT PHARMA APS (DK) | 2016-02-17 | — | — | EP | disclosed |
| EP-2348016-B1 | Phenyl pyrrole aminoguanidine derivatives | SYNACT PHARMA APS (DK) | 2016-02-17 | — | — | EP | disclosed |
| US-8058306-B2 | Phenyl pyrrole aminoguanidine derivatives | ACTION PHARMA A/S (DK) | 2011-11-15 | — | — | US | disclosed |
| US-8058306-B2 | Phenyl pyrrole aminoguanidine derivatives | ACTION PHARMA A/S (DK) | 2011-11-15 | — | — | US | disclosed |
| EP-2348016-A1 | Phenyl pyrrole aminoguanidine derivatives | Action Pharma A/S (DK) | 2011-07-27 | — | — | EP | disclosed |
| EP-2348016-A1 | Phenyl pyrrole aminoguanidine derivatives | Action Pharma A/S (DK) | 2011-07-27 | — | — | EP | disclosed |
| EP-2035373-B1 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES | ACTION PHARMA AS (DK) | 2011-05-04 | — | — | EP | disclosed |
| EP-2035373-B1 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES | ACTION PHARMA AS (DK) | 2011-05-04 | — | — | EP | disclosed |
| US-20110082183-A1 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES | ACTION PHARMA A/S (DK) | 2011-04-07 | — | — | US | disclosed |
| US-20110082183-A1 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES | ACTION PHARMA A/S (DK) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082183-A1 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES | MC1R, MC5R, MC4R | GAA 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.